EyePoint Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2025
0mins
Source: Globenewswire
Stock Options Granted: EyePoint Pharmaceuticals announced the granting of non-statutory stock options to three new employees, totaling 13,500 shares, as inducement awards outside the 2023 Long-Term Incentive Plan, with an exercise price of $11.73 per share.
DURAVYU Development: The company is advancing its lead product candidate, DURAVYU, an investigational treatment for serious retinal diseases, currently undergoing Phase 3 trials for wet age-related macular degeneration and diabetic macular edema, with data expected in mid-2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
